Nagalakshmi Nadiminty

TL;DR: These findings offer preclinical validation of niclosamide as a promising inhibitor of AR variants to treat, either alone or in combination with current antiandrogen therapies, patients with advanced prostate cancer, especially those resistant to enzalutamide.

TL;DR: Targeting intracrine androgens and AKR1C3 will overcome enzalutamide resistance and improve survival of advanced prostate cancer patients.

TL;DR: The study demonstrates that the miRNA let-7c plays an important role in the regulation of androgen signaling in prostate cancer by down-regulating AR expression, and suggests that reconstitution of miR-let- 7c may aid in targeting enhanced and hypersensitive AR in advanced prostate cancer.

TL;DR: It is demonstrated that resistance to enzalutamide may be mediated by NF-κB2/p52 via activation of AR and its splice variants through activation of aberrant androgen receptor (AR) activation and AR splice variant production.

TL;DR: It is demonstrated that microRNA let-7c is downregulated in PCa and functions as a tumor suppressor, and is a potential therapeutic target for PCa.